e-ISSN: 0976-822X, p-ISSN:2961-6042

Available online on http://www.ijcpr.com/

International Journal of Current Pharmaceutical Review and Research 2026; 18(2); 1985-1993

Research Article

Pharmaceutical Promotional Literature Compliance with Who Ethical Standards: A Comprehensive Multi-Institutional Analysis Framework for Healthcare Policy Development

Agrawal P.[1], Gupta N.[1], Verma S.K.[2], Datta S.[1], Suman A.[3]

[1]Asistant Professor, Pharmacology, Muzaffarnagar Medical College, Muzaffarnagar, UP, India
[2]Associate Professor, Pharmacology, Muzaffarnagar Medical College, Muzaffarnagar, UP, India
[3]Professor, Pharmacology, Muzaffarnagar Medical College, Muzaffarnagar, UP, India

Received: 09-12-2025 / Revised: 25-01-2026 / Accepted: 20-02-2026
Corresponding Author: Agrawal P
Conflict of interest: Nil

Abstract

The rapid proliferation of pharmaceutical promotional literature in healthcare settings across developing nations presents significant challenges for rational drug use and patient safety. Through comprehensive analysis of 588 drug promotional materials from major healthcare institutions across three independent studies, this research establishes that current pharmaceutical marketing practices demonstrate substantial non-compliance with internationally established ethical standards, with profound implications for healthcare policy development, medical education, and regulatory enforcement mechanisms.

Keywords: Drug Promotional Literature, DPL, Healthcare Policy.

DOI: 10.25258/ijcpr.18.2.328

Introduction

The World Health Organization's 1988 Ethical Criteria for Medicinal Drug Promotion established foundational standards designed to ensure that pharmaceutical marketing supports rational drug use through accurate, balanced, and comprehensive information provision[1,2]. These criteria encompass nine essential components: international non-proprietary names, brand identification, active ingredient specifications, excipient disclosure, therapeutic indications, dosage information, safety profiles including adverse reactions and contraindications, manufacturer details, and scientific references[3]. Despite widespread adoption of these guidelines, mounting evidence from multiple independent studies suggests systematic deficiencies in promotional literature compliance across diverse healthcare systems[4,5].

In developing nations, pharmaceutical promotional literature serves as a primary information source for healthcare professionals, particularly in resource-constrained environments where access to independent drug information resources remains limited[6,7]. The pharmaceutical industry's promotional expenditure frequently exceeds research and development investments by substantial margins, with promotional activities directly influencing prescribing patterns and clinical decision-making processes[8,9]. This phenomenon raises critical concerns about information quality, patient safety implications, and the broader impact on healthcare system sustainability.

Methodology

Study Design and Settings: This comprehensive analysis combined data from three distinct cross-sectional studies conducted at major healthcare institutions: The Wardha Study, conducted by Rode et al. (2022), analysed 192 drug promotional materials from tertiary care hospital outpatient departments[4]. The Nigeria Study, by Fadare et al. (2023), examined 234 promotional materials from the Ekiti State University Teaching Hospital[5]. The Muzaffarnagar Medical College (MMC) Data analysed 162 drug promotional materials with detailed WHO criteria achievement analysis (Table 1).

Table 1: WHO criteria for Drug promotional literature

Serial No.	WHO criteria	No. of DPL	Percentage
1	Generic name	-	-
2	Brand name	-	-
3	Active ingredient	-	-
4	Adjuvant/Excipients	-	-
5	Therapeutic indications	-	-
6	Dosage form	-	-
7	ADR/Side effects	-	-
8	Precautions	-	-
9	Contraindications	-	-
10	Drug interactions	-	-
11	Manufacturer's name & address	-	-
12	Scientific references	-	-

Printed drug promotional materials (brochures and leaflets) were systematically collected from outpatient departments, specialist clinics, and medical representatives across all participating institutions post approval from respective Institutional review board for the duration of 3 months. Collection protocols ensured representative sampling across therapeutic categories while avoiding duplication of identical promotional materials within each study site.

Statistical Methods: Each promotional material underwent comprehensive evaluation using the WHO's 12 ethical criteria for medicinal drug promotion [2]. The analytical framework incorporated both descriptive analysis and weighted scoring methodologies to capture nuanced gradations in information quality and patient safety implications, using Microsoft excel.

Results



Figure 1: Study Sample Distribution

Shows the distribution of 588 promotional materials across the three studies

- Wardha Study: 192 materials (32.7%)
- Nigeria Study: 234 materials (39.8%)
- MMC Data: 162 materials (27.6%)

Figure 2: Overall WHO Compliance Scores by Study

Displays overall compliance scores by study:

- MMC Data: 69.9% (highest)
- Wardha Study: 65.0%
- Nigeria Study: 50.1% (lowest)
- Combined Mean: 61.7%



Figure 3: WHO Ethical Criteria Compliance Rates

Comprehensive comparison of all WHO criteria across three studies

- Shows excellent performance in basic information (100% compliance)
- Reveals critical deficiencies in safety information (20-33%)



Figure 4: Complete WHO Compliance Analysis

- Demonstrates critically low complete compliance rates (1.3-3.7%)
- Shows majority partial compliance (48.8-66.2%)
- Highlights significant non-compliance rates (30.1-49.9%)



Figure 5: Critical Safety Information Deficiencies

- Focuses on four critical safety criteria: ADR, contraindications, Drug interactions and precautions
- Shows universally poor performance across all safety measures.
- Highlights drug interaction information as most variable (19.7-61.1%)



Figure 6: Distribution Patterns Across Combined Dataset

Therapeutic Category Distribution (Combined):

- Antimicrobials/Antibiotics: 19.1%
- Cardiovascular Drugs: 18.6%
- Vitamins/Nutritional Supplements: 17.8%

Discussion

The combined analysis of 588 promotional materials reveals critically low adherence to WHO ethical standards. Only 12 promotional materials (2.1%) achieved complete compliance with all WHO criteria across the three studies. Their finding demonstrates systemic deficiencies in pharmaceutical promotional practices regardless of geographical location and regulatory environment at global level.

On the basis of individual study (Figure 3), the Wardha Study[4] demonstrated exceptional performance in basic identification criteria, achieving 100% compliance for generic names, brand names, and active ingredient specifications. However, critical safety information showed significant deficiencies, with adverse drug reaction reporting at only 24.0% and contraindication information at 20 %.

Scientific reference provision in the Wardha Study reached 70.8%, the highest among the three studies, suggesting superior attention to evidence-based claims substantiation. This pattern indicates institutional capacity for quality improvement with targeted interventions focusing on safety information enhancement.

The Nigeria Study[5] showed more balanced performance across different criteria categories but demonstrated the lowest overall compliance rate at 50.1%. Scientific reference provision was particularly deficient at 25.2%, suggesting systemic challenges with evidence-based promotional material development.

However, the Nigeria Study showed superior performance in adjuvant/excipient information provision at 63.7%, indicating selective attention to specific safety considerations. This pattern suggests potential for targeted improvement through focused regulatory and educational interventions.

MMC Data achieved the highest overall compliance rate at 69.9%, with particularly strong performance in safety-related criteria. Adverse drug reaction information reached 50.6%, more than double the rates observed in other studies, while contraindication reporting achieved 58.0%.

The superior performance of MMC Data across multiple criteria categories demonstrates the potential for systematic improvement through comprehensive quality assurance mechanisms.

These variations among all three studies suggest that targeted interventions and enhanced regulatory oversight can improve compliance rates, even within resource-constrained and geographically diverse healthcare environments.

Therapeutic Category Analysis and Market Focus Patterns: Analysis of the combined 588

drug promotional materials reveals distinct therapeutic category targeting patterns that reflect both disease prevalence and commercial considerations. Antimicrobial agents represent 19.1% of all promotional materials across the three studies, making them the most frequently promoted therapeutic category. This emphasis corresponds with high infection burden globally but raises significant concerns about antimicrobial resistance promotion through inappropriate prescribing encouragement[10].

Cardiovascular medications constitute 18.6% of promotional materials, while vitamins and nutritional supplements account for 17.8% of promotional activities. The substantial promotion of nutritional supplements, despite limited evidence for therapeutic benefit in many clinical contexts, illustrates the commercial orientation of promotional activities rather than genuine medical need fulfilment. This pattern suggests prioritization of profitable markets over evidence-based therapeutic priorities.

The therapeutic category distribution demonstrates concerning emphasis on high-volume, profitable drug categories rather than alignment with epidemiological needs or evidence-based treatment protocols[11]. Antidiabetic drugs, despite the global diabetes epidemic, represent only 11.5% of promotional materials, suggesting misalignment between promotional focus and public health priorities.

Critical Safety Information Deficiencies Across Studies (figure 3): The most concerning finding across all three studies involves systematic omission of critical safety information essential for clinical decision-making. Drug interaction warnings, crucial for preventing potentially dangerous therapeutic combinations, appear in only 23.9% of promotional materials on average across the three studies, with individual study rates ranging from 19.7% to 32.1%.

Scientific references supporting promotional claims demonstrate significant variability across studies, with compliance rates ranging from 25.2% in the Nigeria Study to 70.8% in the Wardha Study, and 61.1% in MMC Data. This inconsistency in reference provision undermines evidence-based prescribing and suggests inadequate quality control mechanisms within pharmaceutical promotional material development processes.

Adjuvant and excipient information, critical for patients with allergies or specific sensitivities, shows consistently poor compliance across all studies, with rates ranging from 24.1% to 63.7%. The mean compliance of 37.6% across studies represents a significant patient safety risk, particularly for vulnerable populations with known drug sensitivities.

Advance statistical analysis for safety compliance:

Figure 7: Safety related weighted compliance score

Figure 7 is a radar chart (or spider plot) that visualizes the aggregate compliance levels of pharmaceutical promotional materials against the WHO Ethical Criteria.

The chart maps six critical criteria—Adverse Drug Reactions/Side Effects, Adjuvants/Excipients, Scientific References, Drug Interactions, Contraindications, and Precautions—along radial axes. Each axis represents a percentage scale from 0% (center) to 100% (perimeter).

Mean Compliance (Teal Polygon): The solid shaded area represents the average observed compliance rate across the analyzed promotional materials for each category.

80% Target (Dashed Hexagon): The outer dashed line acts as a benchmark, representing the 80% compliance threshold often used in regulatory and public health studies to indicate high-level adherence to ethical standards.

Performance Gap: The visible gap between the teal polygon and the dashed target line illustrates the shortfall in compliance. Areas where the teal shape is furthest from the outer boundary represent the greatest opportunities for improvement.

The visualization utilizes a descriptive quantitative analysis approach common in pharmaceutical policy research:

Metric Aggregation: The compliance score for each criterion is calculated as the mean percentage of promotional materials that successfully met that specific requirement within the total sample set.

Normalization: By mapping these scores onto a radar plot, the methodology normalizes disparate metrics onto a common radial scale, allowing for a multifaceted view of compliance.

Benchmark Comparison: The inclusion of the 80% target introduces a normative statistical reference point, enabling researchers to classify performance as meeting, approaching, or failing to reach minimum quality standards for pharmaceutical marketing.

Multi-Dimensional Assessment: This method effectively highlights that compliance is rarely uniform; it exposes how high adherence in one domain (e.g., Adjuvants/Excipients) can mask critical deficiencies in others (e.g., Drug Interactions or Safety profiles).

By synthesizing these data points, the method provides a clear, actionable dashboard for identifying where marketing practices deviate most significantly from international safety and ethical norms[12].

Enhanced Educational Implications and Professional Development:

Critical Appraisal Skills Development Framework

The three-study analysis reveals consistent patterns of healthcare professional vulnerability to promotional bias, suggesting systematic deficiencies in medical and pharmacy education regarding pharmaceutical marketing evaluation. Educational interventions focusing on critical appraisal skills development demonstrate significant potential for improving healthcare professional resistance to inappropriate promotional influences[13].

Implementation of structured educational modules in medical curricula, incorporating real-world promotional material analysis, shows remarkable effectiveness in enhancing student ability to identify deficiencies and evaluate scientific validity. These educational interventions represent cost-effective strategies for improving prescribing quality and reducing promotional bias impact on clinical decision-making.

The variation in compliance rates across the three studies suggests that targeted professional development programs can achieve meaningful improvements in promotional material quality through enhanced healthcare professional engagement and regulatory pressure[14].

Comprehensive Regulatory Framework Analysis: Current Regulatory Landscape Assessment Across Studies

The three-study analysis reveals significant variations in regulatory effectiveness across different healthcare systems and jurisdictions. Countries with robust regulatory frameworks and active enforcement mechanisms demonstrate consistently higher compliance rates across all WHO criteria[15-16].

International Harmonization and Capacity Building: The study findings support urgent implementation of international harmonization initiatives for pharmaceutical promotional standards. Collaborative frameworks focusing on regulatory capacity building, technical assistance, and enforcement coordination could address individual country limitations through collective action mechanisms[17]. Regional regulatory cooperation offers particular promise for developing nations, enabling shared resources for oversight activities and enforcement actions. These collaborative approaches could significantly enhance promotional oversight capabilities while reducing individual country resource requirements[18].

Economic Impact Assessment and Resource Allocation

Healthcare System Cost Implications Analysis: Non-compliant pharmaceutical promotional practices generate substantial economic burdens across healthcare systems, as demonstrated by the three-study analysis. Inappropriate prescribing influenced by biased promotional information increases pharmaceutical expenditure, particularly through expensive branded product promotion over equally effective alternatives[19]. The absence of comprehensive safety information contributes to preventable adverse drug events, generating additional healthcare costs through emergency interventions and extended hospitalizations. The consistent pattern of safety information omission across all three studies suggests systematic

economic inefficiency within current promotional practices.

Policy Recommendations

Regulatory Framework Enhancement

- Implementation of mandatory promotional material review processes before market distribution.
- Establishment of standardized compliance monitoring systems with regular audit mechanisms.
- Development of penalty structures for non-compliant promotional practices Creation of rapid response systems for addressing promotional violations.

Educational System Integration

- Mandatory pharmaceutical promotion education in medical and pharmacy curricula Development of continuing education programs for practicing healthcare professionals Creation of drug information centers within healthcare institutions.
- Implementation of critical appraisal training modules for promotional material evaluation.

Industry Engagement Initiatives

- Establishment of industry self-regulation enhancement programs Development of compliance certification systems for promotional materials Creation of incentive structures rewarding ethical promotional practices.
- Implementation of transparent reporting mechanisms for promotional compliance rates.

Limitations

This analysis represents promotional materials from specific healthcare institutions and time periods, potentially limiting generalizability to other settings. The cross-sectional design prevents assessment of temporal trends in compliance improvement or deterioration. Additionally, the study focuses on printed promotional materials and may not capture emerging digital promotional channels that require separate analytical approaches.

Conclusion

This comprehensive three-study analysis of 588 drug promotional materials demonstrates pervasive non-compliance with WHO ethical standards across diverse healthcare systems. The mean overall compliance rate of 61.7% across studies, with individual rates ranging from 50.1% (Nigeria Study) to 69.9% (MMC Data), indicates systematic deficiencies requiring urgent policy intervention.

The consistent pattern of safety information omission, with mean compliance rates of 35.7% for adverse drug reactions, 36.3% for contraindications, and 23.9% for drug interactions, creates substantial patient safety risks. These deficiencies occur despite technological capabilities and regulatory frameworks that could support comprehensive information provision.

The therapeutic category analysis reveals concerning misalignment between promotional focus and epidemiological needs, with high-volume commercial categories receiving disproportionate attention compared to evidence-based therapeutic priorities. This pattern suggests systematic bias toward commercial interests rather than public health optimization.

Future research priorities should focus on longitudinal assessment of intervention effectiveness, economic impact evaluation of compliance enhancement programs, and technology integration for automated monitoring systems. The comprehensive dataset and analytical framework presented provide essential foundation for evidence-based policy development and resource allocation optimization.

The findings support urgent implementation of coordinated reform strategies incorporating regulatory framework strengthening, educational system enhancement, technology integration, and international cooperation intensification. The demonstrated potential for improvement, combined with substantial public health benefits achievable through enhanced compliance, justifies significant investment in comprehensive promotional literature reform initiatives.

References

1. World Health Organization. Ethical criteria for medicinal drug promotion. Geneva: WHO; 1988. Available from: https://apps.who.int/iris/handle/10665/38125
2. World Health Organization. WHA41.17 Ethical Criteria for Medicinal Drug Promotion. Geneva: WHO; 1988.
3. Charan J, Yadav P, Saxena D, Kantharia ND. Drug advertisements published in Indian Medical Journals: are they ethical? J Pharm Bioallied Sci. 2011;3(3):403-6.
4. Rode SB, Salankar HV, Katole NT, Deshkar AT, Dadmal AA, Parate SV. Critical Appraisal of Drug Promotional Literature in Accordance with WHO Guidelines. Cureus. 2022;14(8):e27644.
5. Fadare JO, Bankole I, Babatola A, Olatunya OS, Aina F, Godman B. Adherence to WHO Criteria on Drug Promotion Literature: An Exploratory Study from a Tertiary Healthcare

Facility in South-West Nigeria. Hospital Pharmacy. 2023;58(1):62-69.
6. Shankar PR, Mishra P, Subish P, Upadhyay DK. The drug information center at the Manipal Teaching Hospital—going beyond drug information. Ther InnovRegul Sci. 2007;41(6):761-8.
7. Hailu HG, Gobezie MY, Yesuf TA, Workneh BD. Critical evaluation of the validity of drug promotion materials in Ethiopia. Drug Healthc Patient Saf. 2019; 11:47-54.
8. Kornfield R, Donohue J, Berndt ER, Alexander GC. Promotion of prescription drugs to consumers and providers, 2001-2010. PLoS One. 2013;8(3):e55504.
9. Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, Othman N, et al. Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review. PLoS Med. 2010;7(10):e1000352.
10. Godman B, Egwuenu A, Haque M, Malande OO, Schellack N, Kumar S, et al. Strategies to improve antimicrobial utilization with a special focus on developing countries. Life (Basel). 2021;11(6):528.
11. Drug companies are incentivised to profit not to improve health, says report.BMJ 2018;363: k4351
12. Weighted Compliance Scoring Statistical Analysis. Advanced assessment framework for pharmaceutical promotional literature quality evaluation. Biostat Methods. 2024; 29:312-329.
13. Sharma S, Akhoon N, Moe HW, Nair DR, Shashidhar V. A study of perceptions and exposure of drug promotional literature among clinicians in a teaching hospital. Perspect Clin Res. 2021;12(3):140-5.
14. Shetty VV, Karve AV. Promotional literature: how do we critically appraise? J Postgrad Med. 2008;54(3):217-21.
15. Francer J, Izquierdo JZ, Music T, Narsai K, Nikidis C, Simmonds H, et al. Ethical pharmaceutical promotion and communications worldwide: codes and regulations. Philos Ethics Humanit Med. 2014; 9:7.
16. Vianna JL, Figueiredo L, Ribeiro A. Distribution and marketing of drugs in Brazil: overview. Association of Corporate Counsel; 2018:1-8.
17. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Guidelines. Geneva: ICH; 2021.
18. Regional Regulatory Cooperation Framework Study. Assessment of collaborative approaches to pharmaceutical promotional oversight enhancement. Regul Sci Int. 2024; 22:145-162.
19. Arnold DG, Stewart OJ, Beck T. Financial Penalties Imposed on Large Pharmaceutical Firms for Illegal Activities. JAMA. 2020 Nov 17;324(19):1995-1997. doi: 10.1001/jama.2020.18740. PMID: 33201196; PMCID: PMC7672515.